contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


number-of-shares-and-votes-in-oncopeptides-8

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Oncopeptides är ett bioteknikbolag som utvecklar läkemedel för svårbehandlade hematologiska sjukdomar. Bolaget använder sin PDC-plattform för att ta fram peptidlänkade läkemedel som selektivt levererar cellgifter in i cancerceller. Bolaget har läkemedel för kommersialisering, och har flera läkemedelskandidater under utveckling. Oncopeptides huvudkontor ligger i Stockholm.

Oncopeptides

Stockholm — 28 February, 2025 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes ...

<div class="mfn-preamble"><p><strong>Stockholm — 28 February, 2025 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s issue of 10,572,577 new class C shares. The shares are issued by virtue of the Annual General Meetings’ resolution on 31 May 2024 on authorisation for the Board of Directors to resolve on issue of class C shares to enable delivery of shares to participants under the incentive programs Co-worker LTIP 2022, Co-worker LTIP 2024 and Board SHP 2024 as well as other outstanding shareholder programs for members of the Board of Directors.</strong></p></div><div class="mfn-body"><p>Before the share issue, the total number of shares in Oncopeptides amounted to 215,186,246 and the total number of votes in Oncopeptides amounted to 211,656,137.3. As a result of the share issue, the number of shares in Oncopeptides has increased by 10,572,577 class C shares, corresponding to 1,057,257.7 votes. As of today, the total number of shares in Oncopeptides amounts to 225,758,823 shares, of which 211,263,903 are ordinary shares and 14,494,920 are class C shares. The number of votes in Oncopeptides as of today amounts to 212,713,395. The share capital has increased by SEK 1,174,730.825486 from SEK 23,909,583.859895 to SEK 25,084,314.685381.</p></div><div class="mfn-footer mfn-contacts mfn-ad2e6a7e9211"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)<br>E-mail: <a rel="noopener" href="mailto:david.augustsson@oncopeptides.com">david.augustsson@oncopeptides.com</a><br>Cell phone: +46 76 229 38 68</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-lhfi"><p><em>This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-02-28 17:50 CET.</em></p></div><div class="mfn-footer mfn-about mfn-05abf943815f"><p><strong class="mfn-heading-1">About Oncopeptides</strong><br>Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.&nbsp;</p><p>The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.&nbsp;Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.</p><p>Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.</p><p>The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed&nbsp;on Nasdaq Stockholm with the ticker ONCO.</p><p>For more information see:&nbsp;<a rel="noopener" href="http://www.oncopeptides.com/en">www.oncopeptides.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/ce38dd3f-4f6d-4513-a857-990ff3009efe/number-of-shares-and-votes-in-oncopeptides.pdf" class="mfn-generated mfn-primary">Number of shares and votes in Oncopeptides</a></p></div>